Recommendations of the chilean association for digestive endoscopy for the management of gastric pre-malignant lesions;Diagnóstico precoz de cancer gástrico. Propuesta de detección y seguimiento de lesiones premalignas gástricas: Protocolo ached

Revista Medica de Chile

Volumn 142, Issue 9, 2014, Pages 1181-1192

  Rollán, Antonio ^a   Cortés, Pablo ^a   Calvo, Alfonso ^b   Araya, Raúl ^c   Bufadel, María Ester ^d   González, Robinson ^e   Heredia, Carolina ^f   Muñoz, Pablo ^d   Squella, Freddy ^g   Nazal, Roberto ^h   Gatica, María de Los Ángeles ^a   Gobelet, Jaquelina ^a   Estay, René ⁱ   Pisano, Raúl ^j   Contreras, Luis ^k   Osorio, Ingrid ^l   Estela, Ricardo ^m   Fluxá, Fernando ⁿ   Parra Blanco, Adolfo ^e  

^a UNIVERSIDAD DEL DESARROLLO   (Chile)

^b HOSPITAL DR SÓTERO DEL RÍO   (Chile)

^c HOSPITAL MILITAR DE SANTIAGO   (Chile)

^d HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^e PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^f UNIVERSIDAD DE LOS ANDES   (Chile)

^g UNIVERSIDAD ANDRÉS BELLO   (Chile)

^h San Jose Hospital   (Chile)

ⁱ CLÍNICA SANTA MARÍA   (Chile)

^j HOSPITAL SAN JUAN DE DIOS   (Chile)

^k Serv Oncol Y Anat Patologica C   (Chile)

^l Hospital El Pino   (Chile)

^m UNIVERSITY OF CHILE   (Chile)

ⁿ CLÍNICA LAS CONDES   (Chile)

more..

Author keywords

Gastric neoplasms; Health planning guidelines; Mass screening

Indexed keywords

CHILE; EARLY DIAGNOSIS; GASTROINTESTINAL ENDOSCOPY; HUMAN; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRECANCEROUS CONDITIONS; PROCEDURES; RISK FACTOR; STOMACH NEOPLASMS;

CHILE; EARLY DETECTION OF CANCER; ENDOSCOPY, GASTROINTESTINAL; HUMANS; PRECANCEROUS CONDITIONS; RISK FACTORS; SOCIETIES, MEDICAL; STOMACH NEOPLASMS;

EID: 84914685807     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: 10.4067/s0034-98872014000900013     Document Type: Article

References (83)

1. Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, et al. Recent patterns in gastric cancer: a global overview. Int J Cancer 2009; 125 (3): 666-73.
2. Cenitagoya GF, Bergh CK, Klinger-Roitman J. A prospective study of gastric cancer. “Real” 5-year survival rates and mortality rates in a country with high incidence. Dig Surg 1998; 15 (4): 317-22.
3. Heise K, Bertran E, Andia ME, Ferreccio C. Incidence and survival of stomach cancer in a high-risk population of Chile. World J Gastroenterol 2009; 15 (15): 1854-62.
4. Correa P. Gastric cancer: overview. Gastroenterol Clin North Am 2013; 42 (2): 211-7.
5. Correa P, Cuello C, Duque E. Carcinoma and intestinal metaplasia of the stomach in Colombian migrants. J Natl Cancer Inst 1970; 44 (2): 297-306.
6. Hamashima C, Shibuya D, Yamazaki H, Inoue K, Fukao A, Saito H, et al. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol 2008; 38 (4): 259-67.
7. Leung WK, Wu M, Kakugawa Y, Kim JJ, Yeoh K, Goh KL, et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol 2008; 9 (3): 279-87.
8. Yuan Y. A survey and evaluation of population-based screening for gastric cancer. Cancer Biol Med 2013; 10 (2): 72-80.
9. Llorens P. Gastric cancer mass survey in Chile. Semin Surg Oncol 1991; 7 (6): 339-43.
10. Calvo Belmar A, Pruyas M, Nilsen E, Verdugo P. [Populational research of gastric cancer in digestive symptomatic patients, from 1996 to 2000]. Rev Med Chile 2001; 129 (7): 749-55.
11. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 2001; 20 (3 Suppl): 21-35.
12. Sawaya GF, Guirguis-Blake J, LeFevre M, Harris R, Petitti D. Update on the methods of the U.S. Preventive Services Task Force: estimating certainty and magnitude of net benefit. Ann Intern Med 2007; 147 (12): 871-5.
13. Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs 2000; 32 (4): 1008-15.
14. Graham D Y, Asaka M. Eradication of gastric cancer and more efficient gastric cancer surveillance in Japan: two peas in a pod. J Gastroenterol 2010; 45 (1): 1-8.
15. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345 (11): 784-9.
16. Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, Nakamura H, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004; 109 (1): 138-43.
17. Fuccio L, Eusebi LH, Bazzoli F. Gastric cancer, Helicobacter pylori infection and other risk factors. World J Gastrointest Oncol 2010; 2 (9): 342-7.
18. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008; 372 (9636): 392-7.
19. Ferreccio C, Rollán A, Harris PR, Serrano C, Gederlini A, Margozzini P, et al. Gastric cancer is related to early Helicobacter pylori infection in a high-prevalence country. Cancer Epidemiol. Biomarkers Prev 2007; 16 (4): 662-7.
20. Ortega JP, Espino A, Calvo B A, Verdugo P, Pruyas M, Nilsen E, et al. Helicobacter pylori infection in symptomatic patients with benign gastroduodenal diseases: analysis of 5.664 cases. Rev Med Chile 2010; 138: 529-35.
21. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009; 24 (10): 1587-600.
22. Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon ATR, Bazzoli F, et al. Management of Helicobacter pylori infection-the Maastricht IV/ Florence Consensus Report. Gut 2012; 61 (5): 646-64.
23. Rollan A, Ferreccio C, Gederlini A, Serrano C, Torres J, Harris P. Non-invasive diagnosis of gastric mucosal atrophy in an asymptomatic population with high prevalence of gastric cancer. World J Gastroenterol 2006; 12 (44): 7172-8.
24. Dinis-Ribeiro M, Areia M, Vries AC De, Pereira C, Correia R, Ensari A, et al. Management of precancerous conditions and lesions in the stomach (MAPS). Guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012; 44 (1): 74-94.
25. La Vecchia C, Negri E, Franceschi S, Gentile A. Family history and the risk of stomach and colorectal cancer. Cancer 1992; 70 (1): 50-5.
26. Yaghoobi M, Bijarchi R, Narod SA. Family history and the risk of gastric cancer. Br J Cancer 2010; 102 (2): 237-42.
27. El-Omar EM, Oien K, Murray LS, El-Nujumi A, Wirz A, Gillen D, et al. Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori. Gastroenterology 2000; 118 (1): 22-30.
28. Marcos-Pinto R, Carneiro F, Dinis-Ribeiro M, Wen X, Lopes C, Figueiredo C, et al. First-degree relatives of patients with early-onset gastric carcinoma show even at young ages a high prevalence of advanced OLGA/ OLGIM stages and dysplasia. Aliment Pharmacol Ther 2012; 35 (12): 1451-9.
29. Rugge M. Secondary prevention of gastric cancer. Gut 2007; 56 (12): 1646-7.
30. Kashiwagi H. Ulcers and gastritis. Endoscopy 2005; 37 (2): 110-5.
31. Lim JH, Kim N, Lee HS, Choe G, Jo SY, Chon I, et al. Correlation between Endoscopic and Histological Diagnoses of Gastric Intestinal Metaplasia. Gut Liver 2013; 7 (1): 41-50.
32. Graham DY, Kato M, Asaka M. Gastric endoscopy in the 21st century: appropriate use of an invasive procedure in the era of non-invasive testing. Dig. Liver Dis 2008; 40 (7): 497-503.
33. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 19Am J Surg Pathol 1996; 20 (10): 1161-81.
34. De Vries AC, Haringsma J, de Vries RA, Ter Borg F, van Grieken NCT, Meijer GA, et al. Biopsy strategies for endoscopic surveillance of pre-malignant gastric lesions. Helicobacter 2010; 15 (4): 259-64.
35. Ezoe Y, Muto M, Uedo N, Doyama H, Yao K, Oda I, et al. Magnifying narrowband imaging is more accurate than conventional white-light imaging in diagnosis of gastric mucosal cancer. Gastroenterology 2011; 141 (6): 2017-25.
36. Ekström AM, Held M, Hansson L-E, Engstrand L, Nyrén O. Helicobacter pylori in Gastric Cancer Established by CagA Immunoblot as a Marker of Past Infection. Gastroenterology 2001; 121 (4): 784-91.
37. Matsuhisa T, Matsukura N, Yamada N. Topography of chronic active gastritis in Helicobacter pylori-positive Asian populations: age-, gender-, and endoscopic diagnosis-matched study. J. Gastroenterol 2004;39(4):324-8.
38. Mukoubayashi C, Yanaoka K, Ohata H, Arii K, Tamai H, Oka M, et al. Serum Pepsinogen and Gastric Cancer Screening. Intern. Med 2007; 46 (6): 261-6.
39. De Vries AC, van Grieken NCT, Looman CWN, Casparie MK, de Vries E, Meijer GA, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 2008; 134 (4): 945-52.
40. Coma del Corral MJ, Pardo-Mindan FJ, Razquin S, Ojeda C. Risk of cancer in patients with gastric dysplasia. Follow-up study of 67 patients. Cancer 1990; 65 (9): 2078-85.
41. Sarela AI, Scott N, Verbeke CS, Wyatt JI, Dexter SPL, Sue-Ling HM, et al. Diagnostic variation and outcome for high-grade gastric epithelial dysplasia. Arch Surg 2005; 140 (7): 644-9.
42. Schlemper RJ, Itabashi M, Kato Y, Lewin KJ, Riddell RH, Shimoda T, et al. Differences in diagnostic criteria for gastric carcinoma between Japanese and western pathologists. Lancet 2007; 349 (9067): 1725-9.
43. Schlemper RJ, Riddell RH, Kato Y, Borchard F, Cooper HS, Dawsey SM, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47 (2): 251-5.
44. Lauwers GY, Carneiro F, Graham DY et al. Gastric carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds.) WHO Classification of tumours of the digestive system. 4 edn. Lyon: IARC Press; 2010; 48-58.
45. Meining A, Bayerdörffer E, Müller P, Miehlke S, Lehn N, Hölzel D, et al. Gastric carcinoma risk index in patients infected with Helicobacter pylori. Virchows Arch 1998; 432 (4): 311-4.
46. Rugge M, Genta RM. Staging gastritis: an international proposal. Gastroenterology 2005; 129 (5): 1807-8.
47. el-Zimaity HM, Graham DY, al-Assi MT, Malaty H, Karttunen TJ, Graham DP, et al. Interobserver variation in the histopathological assessment of Helicobacter pylori gastritis. Hum Pathol 1996; 27 (1): 35-41.
48. Capelle LG, de Vries AC, Haringsma J, Ter Borg F, de Vries RA, Bruno MJ, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest. Endosc 2010; 71 (7): 1150-8.
49. Rugge M, Fassan M, Pizzi M, Farinati F, Sturniolo GC, Plebani M, et al. Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment. World J. Gastroenterol 2011; 17 (41): 4596-601.
50. Rollan A. OLGA System (“Operative Link for Gastritis Assessment”). Gastroenterol latinoam 2012; 23 (2): 53-4.
51. Rugge M, Boni MDE, Lli GP, Bona MDE, Giacomelli L, Fassan M. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther 2010; 31 (10): 1104-11.
52. Rugge M, Kim JG, Mahachai V, Miehlke S, Pennelli G, Russo VM, et al. OLGA gastritis staging in young adults and country-specific gastric cancer risk. Int J Surg Pathol 2008; 16 (2): 150-4.
53. Satoh K, Osawa H, Yoshizawa M, Nakano H, Hirasawa T, Kihira K, et al. Assessment of atrophic gastritis using the OLGA system. Helicobacter 2008; 13 (3): 225-9.
54. Carrasco G, Corvalan AH. Helicobacter pylori-Induced Chronic Gastritis and Assessing Risks for Gastric Cancer. Gastroenterol Res Pract 2013; 2013: 393015.
55. Tsai Y-C, Hsiao W-H, Yang H-B, Cheng H-C, Chang W-L, Lu C-C, et al. The corpus-predominant gastritis index may serve as an early marker of Helicobacter pylori-infected patients at risk of gastric cancer. Aliment Pharmacol Ther 2013; 37 (10): 969-78.
56. Rollan A, Giancaspero R, Fuster F, Acevedo C, Figueroa C, Hola K, et al. The long-term reinfection rate and the course of duodenal ulcer disease after eradication of Helicobacter pylori in a developing country. Am J Gastroenterol 2000; 95 (1): 50-6.
57. Malfertheiner P. Gastric Atrophy Reversible or Irreversible after Helicobacter pylori Eradication-An Open Question. Digestion 2011; 83 (4): 250-2 2011; 250-2.
58. Wang J, Xu L, Shi R, Huang X, Li SWH, Huang Z, et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion 2011; 83 (4): 253-60.
59. You W, Brown LM, Zhang L, Li J, Jin M, Chang Y, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J. Natl. Cancer Inst 2006; 98 (14): 974-83.
60. Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann. Intern. Med 2009;151(2):121-8.
61. Take S, Mizuno M, Ishiki K, Yoshida T, Ohara N, Yokota K, et al. The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori. J Gastroenterol 2011; 46 (3): 318-24.
62. Whiting JL, Sigurdsson A, Rowlands DC, Hallissey MT, Fielding JWL. The long term results of endoscopic surveillance of premalignant gastric lesions. Gut 2002; 50 (3): 378-81.
63. Dan YY, So JBY, Yeoh KG. Endoscopic screening for gastric cancer. Clin. Gastroenterol. Hepatol 2006; 4 (6): 709-16.
64. Shin WG, Kim HU, Song HJ, Hong SJ, Shim K-N, Sung I-K, et al. Surveillance strategy of atrophic gastritis and intestinal metaplasia in a country with a high prevalence of gastric cancer. Dig Dis Sci 2012; 57 (3): 746-52.
65. Zullo A, Hassan C, Romiti A, Giusto M, Guerriero C, Lorenzetti R, et al. Follow-up of intestinal metaplasia in the stomach: When, how and why. World J. Gastrointest. Oncol 2012; 4 (3): 30-6.
66. Yeh JM, Hur C, Kuntz KM, Ezzati M, Goldie SJ. Costeffectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer. Cancer 2010; 116 (12): 2941-53.
67. Hassan C, Zullo A, Di Giulio E, Annibale B, Lahner E, De Francesco V, et al. Cost-effectiveness of endoscopic surveillance for gastric intestinal metaplasia. Helicobacter 2010; 15 (3): 221-6.
68. Dixon MF. Gastrointestinal epithelial neoplasia: Vienna revisited. Gut 2002; 51 (1): 130-1.
69. Kotwal AA, Mohile SG, Dale W. Remaining Life Expectancy Measurement and PSA Screening of Older Men. J Geriatr Oncol 2012; 3 (3): 196-204.
70. Qaseem A, Denberg TD, Jr RHH, Humphrey LL, Levine J. Screening for Colorectal Cancer: A Guidance Statement From the. Ann Intern Med 2012; 156 (5): 378-86.
71. Qaseem A, Barry MJ, Denberg TD, Owens DK, Shekelle P. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 2013; 158 (10): 761-9.
72. Matsumoto S, Yamasaki K, Tsuji K, Shirahama S. Results of mass endoscopic examination for gastric cancer in Kamigoto Hospital, Nagasaki Prefecture. World J Gastroenterol 2007; 13 (32): 4316-20.
73. Jung K-W, Park S, Kong H-J, Won Y-J, Boo Y-K, Shin H-R, et al. Cancer statistics in Korea: incidence, mortality and survival in 2006-20J Korean Med Sci 2010; 25 (8): 1113-21.
74. Suvakovic Z, Bramble MG, Jones R, Wilson C, Idle N, Ryott J. Improving the detection rate of early gastric cancer requires more than open access gastroscopy: a five year study. Gut 1997; 41 (3): 308-13.
75. Yamazato T, Oyama T, Yoshida T, Baba Y, Yamanouchi K, Ishii Y, et al. Two Years’ Intensive Training in Endoscopic Diagnosis Facilitates Detection of Early Gastric Cancer Intern Med 2012; 51 (12): 1461-5.
76. Lee GJ, Park SJ, Kim SJ, Kim HH, Park MI, Moon W. Effectiveness of Premedication with Pronase for Visualization of the Mucosa during Endoscopy: A Randomized, Controlled Trial. Clin Endosc 2012; 45 (2): 161-4.
77. Neale JR, James S, Callaghan J, Patel P. Premedication with N-acetylcysteine and simethicone improves mucosal visualization during gastroscopy: a randomized, controlled, endoscopist-blinded study. Eur J Gastroenterol Hepatol 2013; 25 (7): 778-83.
78. Chen M-J, Wang H-Y, Chang C-W, Hu K-C, Hung C-Y, Chen C-J, et al. The add-on N-acetylcysteine is more effective than dimethicone alone to eliminate mucus during narrow-band imaging endoscopy: a double-blind, randomized controlled trial. Scand. J. Gastroenterol 2013; 48 (2): 241-5.
79. Bhandari P, Green S, Hamanaka H, Nakajima T, Matsuda T, Saito Y, et al. Use of Gascon and Pronase either as a pre-endoscopic drink or as targeted endoscopic flushes to improve visibility during gastroscopy: a prospective, randomized, controlled, blinded trial. Scand. J. Gastroenterol 2010; 45 (3): 357-61.
80. Kato M, Kaise M, Yonezawa J, Toyoizumi H, Yoshimura N, Yoshida Y, et al. Magnifying endoscopy with narrowband imaging achieves superior accuracy in the differential diagnosis of superficial gastric lesions identified with white-light endoscopy: a prospective study. Gastrointest Endosc 2010; 72 (3): 523-9.
81. Zhang J, Guo S-B, Duan Z-J. Application of magnifying narrow-band imaging endoscopy for diagnosis of early gastric cancer and precancerous lesion. BMC Gastroenterol 2011; 11: 135.
82. Emura F, Gralnek I, Baron TH. Improving early detection of gastric cancer: a novel systematic alphanumericcoded endoscopic approach. Rev. Gastroenterol. Peru 2013; 33 (1): 52-8.
83. Lee TJW, Rutter MD, Blanks RG, Moss SM, Goddard AF, Chilton A, et al. Colonoscopy quality measures: experience from the NHS Bowel Cancer Screening Programme. Gut 2012; 61 (7): 1050-7.